• Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in ...
  Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial.

  J Clin Oncol. 2012 Feb 1 ;30(4):347-50. Epub 2011 Dec 27 .
  PubMed
• Effect of early palliative care on chemotherapy use and end-of-life care in pati...
  Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer.

  J Clin Oncol. 2012 Feb 1 ;30(4):394-400. Epub 2011 Dec 27 .
  PubMed
• Phase II, open-label, randomized, multicenter study comparing the efficacy and s...
  Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.

  J Clin Oncol. 2012 Feb 1 ;30(4):372-9. Epub 2011 Dec 27 .
  PubMed
• Endocrine basis for growth-promoting therapy.
  Endocrine basis for growth-promoting therapy.

  Acta Paediatr Scand Suppl. 1990 ;367:11-3.
  PubMed
• Rate of decline of forced vital capacity predicts future arterial hypertension: ...
  Rate of decline of forced vital capacity predicts future arterial hypertension: the Coronary Artery Risk Development in Young Adults Study.

  Hypertension. 2012 Feb ;59(2):219-25. Epub 2011 Dec 27 .
  PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on